This represents a unique opportunity to investigate specific therapies in tumours with different pathological and molecular features as already demonstrated, utilizing our NSCLC PDX platform, for bevacizumab-treated LKB1 mutated tumours39. Here, STK11 is linked to non-small cell lung carcinoma.